Pharmacological intervention for clozapine-induced hypersalivation in schizophrenia - THE LEADERS GUIDE

Produced by the Editorial base of the Cochrane Schizophrenia Group
http://szg.cochrane.org/en/index.html email: jun.xia@nottingham.ac.uk

from

Background explanation

Thank you for giving this guide a go. The idea behind this is to make things easier for you when you lead the journal club.

Journal clubs are often difficult to conduct and far removed from clinical life. Even if the leaders do prepare well, those turning up may be more in need of lunch, coffee or a social time than practical academic stimulation and the implicit pressure to read a difficult paper.

This suggested design is an attempt to allow for those needs, whilst getting the very best out of the session.

What you will need to do is:

☑ Have a good read of this
☑ Then read the review to which this is attached.
☑ Distribute the review to those attending well before the club
☑ Make more copies for those turning up on spec
☑ Do not really expect many to have read the review

The three parts

Part 1. Set the clinical scene (5 mins)

Be clear, but really make the participants feel the pressure of the situation...just like you would in clinical life

Part 2. Critical appraisal of the review (20 mins)

Get participants to list what is needed from the review before Joe and parents arrive, get them to talk, split into groups—with a feeling of urgency.

Part 3. Use of evidence in clinical life (20 mins)

Having distilled the evidence use role play to see how the participants would use what they have learned in everyday life.

Special points of interest:

- This should take no longer than 1 hour to prepare
- First time you undertake a journal club in this way it may be a bit nerve-wracking but....
- It should be fun to conduct and attend
- It should begin and end on the practical day-to-day clinical situation

Inside this guide:

Part 1.1 Setting the scene 2
Part 2.1-2 Critical appraisal 2-3
Part 2.3 Doing the appraisal 3
Part 2.4 A quick and dirty way to work out NNT 4
Part 3. Service user arrives 4
Participants’ worksheet 5–6
Participants crib sheet 7
Feedback sheet 8

PRINTING GUIDE

Pages 1-4 - one copy for you
Pages 5-6 - one copy for each participant - distributed at start of journal club
Page 7— one copy for each participant distributed at end of journal club
Page 8 - one copy for you to collate feedback
Full review for everyone
Try to find a colour printer that does double sided printing

Produced by the Editorial base of the Cochrane Schizophrenia Group
http://szg.cochrane.org/en/index.html email: jun.xia@nottingham.ac.uk

from
Part 1.1 Setting the scene – Joe

Introduce participants in the journal club to their scenario

Joe is a 31 year old man you see in clinic who is articulate and inquisitive. He has been suffering from schizophrenia for the last five years and having tried various antipsychotics which were ineffective, he is now on Clozapine for the last six months which he takes at a dose of 450 mg a day in divided doses.

At this dose, the voices he has been hearing are more bearable and his paranoia has improved. Any increase in dose results in excessive sedation and affects his day to day functioning. A reduction in dose results in worsening of the voices as well as his paranoia.

He has suffered from hypersalivation for the last six months that has been troublesome and he wakes up in the morning with a very wet pillow and he has been considering stopping Clozapine as a result of this.

You have been taught that Propantheline is useful in the treatment of hypersalivation induced by Clozapine and think that this may help Joe. You also know that he will ask you to the-point questions.

Questions for participants:

Q 1. What do you think Joe may ask?
A 1. [Suggestion] “Well, doc, what are my odds of getting better?”
Q 2. What do you think Joe means by ‘better’?
A 2. List the suggestions from participants as these are what Joe will come back to in the role play
Q 3. What do you think Joe’s parents will ask?
A 3. Again, list answers.

Part 1.2 Setting the scene – the Journal club

Complicate the scenario by adding the need to attend this journal club

Knowing you are due to see Joe in less than an hour you are nevertheless compelled to attend journal club.

You have not had time to read the paper and need some lunch.

By a stroke of luck the paper for discussion focuses the pharmacological intervention for Clozapine induced hyper salivation.

Questions for participants:

Q 1. If you had not had this paper fall into your lap where might you have gone for reliable information?
A 1. There are now lots of answers to this - The Cochrane Library, Clinical Evidence, NICE Technology Appraisals.

Anything that has a reproducible method by which results are obtained.

List 2:

1.
2.
3.
4.
5.

Part 2.1 Critical appraisal of the review

For every review there are only three important questions to ask:

1. Are the results valid?

2. What are the results?

3. Are the results applicable to Joe?

You now have only 20 mins to get participants though this large review. To do this quickly is not easy, especially as many will not have read the paper in preparation.

Suggestion: Ask participants what salient facts they want to know - especially considering their tight time-scale.

Remind them that Joe now arrives in about 20 mins.

You should be able to fit most of the suggestions supplied by participants into the three categories of question outlined above.

Read 2.2 as this gives more detail of the issues that will, in some shape or form, be supplied by the participants.

If they are not lively—give them a hand.

Do not panic. Bright journal club attendees will come up with all the answers—your job is to help focus their efforts and categorise their answers.

Do not be worried by silence.

Participants will think of most of the issues - you just need to catch them and write them on a board or flipchart.

Take time to read and think about the review - this is the only time-consuming bit
Part 2.2 The three parts of appraising a review

1. Are the results valid?
   There is no point looking at the result if they are clearly not valid.

   a. Did the review address a clearly focused issue?
   Did the review describe the population studied, intervention given, outcomes considered?

   b. Did the authors select the right sort of studies for the review?
   The right studies would address the review’s question, have an adequate study design

   c. Do you think the important, relevant studies were included?
   Look for which bibliographic databases were used, personal contact with experts, search for unpublished as well as published studies, search for non-English language studies

   d. Did the review’s authors do enough to assess the quality of the included studies?
   Did they use description of randomization, a rating scale?

2. What are the results?
   a. Were the results similar from study to study?
   Are the results of all included studies clearly displayed?
   Are the results from different studies similar?
   If not, are the reasons for variations between studies discussed?

   b. What is the overall result of the review?
   Is there a clinical bottom-line?
   What is it?
   What is the numerical result?

   c. How precise are the results?
   Is there a confidence interval?

3. Can I use the results to help Joe?
   a. Can I apply the results to Joe?
   Is Joe so different from those in the trial that the results don’t apply?

   b. Should I apply the results to Joe?
   How great would the benefit of therapy be for this particular person?
   Is the intervention consistent with Joe’s values and preferences?
   Were all the clinically important outcomes considered?
   Are the benefits worth the harms and costs?

Part 2.3 Doing the appraisal

Having managed the interactive session with the participants – acquiring the three questions that need to be addressed by those appraising a review and some idea of how to answer each of those questions - now divide the room into three.

Apportion one of the questions per group and ask each group to get a feel for the whole review (1 min) but to focus on answering their particular question for the rest of the participants (5 mins or so).

Encourage talking to each other.

Move round the room to help the groups if they seem to need it.

Have your copy of the review marked up with where they may look for answers -although in a good review it should be obvious.

Stop the flow after about 10 minutes and ask each group to report in turn.

Do Group 1 really think that the review uses valid methods? Why?

After the first group’s report you may want to ask everyone to vote whether to proceed or not.

If they agree to proceed —see if you can get Group 2 to give you the clinical bottom line.

We suggest that the Graph providing data for ‘Hypersalivation: 1. No effect/not cured/not markedly improved’ best fits Joe’s request of information about getting ‘better’.

And from Group 3 get some feel of how applicable the findings are.

“Well, Doc, what are my odds of getting better if I take this stuff?”
Part 2.4 A quick and dirty way to work out NNT

COMPARISON 2: ANTIMUSCARINIC: 2. PROPANTHELIN vs CONTROL
Outcome 2.1: Hypersalivation: 1. No effect/not cured/not markedly improved

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Propantheline</th>
<th>Control</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1.1 vs placebo</td>
<td>Events</td>
<td>Total</td>
<td>Weight</td>
<td>M-H, Fixed, 95% CI</td>
</tr>
<tr>
<td>Gong 1998</td>
<td>13</td>
<td>31</td>
<td>39</td>
<td>65.3%</td>
</tr>
<tr>
<td>Lin 1999</td>
<td>13</td>
<td>16</td>
<td>16</td>
<td>34.7%</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>47</td>
<td>55</td>
<td>100.0%</td>
<td>0.59 [0.45, 0.77]</td>
</tr>
<tr>
<td>Total events</td>
<td>26</td>
<td>51</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 7.46, df = 1 (P = 0.006); I² = 87%
Test for overall effect: Z = 3.84 (P = 0.0001)

Total events

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Propantheline</th>
<th>Control</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1.1 vs placebo</td>
<td>Events</td>
<td>Total</td>
<td>Weight</td>
<td>M-H, Fixed, 95% CI</td>
</tr>
<tr>
<td>Gong 1998</td>
<td>13</td>
<td>31</td>
<td>39</td>
<td>65.3%</td>
</tr>
<tr>
<td>Lin 1999</td>
<td>13</td>
<td>16</td>
<td>16</td>
<td>34.7%</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>47</td>
<td>55</td>
<td>100.0%</td>
<td>0.59 [0.45, 0.77]</td>
</tr>
<tr>
<td>Total events</td>
<td>26</td>
<td>51</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 7.46, df = 1 (P = 0.006); I² = 87%
Test for overall effect: Z = 3.84 (P = 0.0001)

26 people out of 47 given Propantheline were not clinically improved in the short term (55%) but 51 people out of 55 allocated to the placebo group did not improve in the short term (93%).

So, because a few people would have got better without Propantheline, the proportion attributable to taking Propantheline, according to these results, is the difference between the groups (or 93% minus 55% = 38%). Just round up or down to make it easy. Lets say, in this case, 40%.

So 40% of people in these trials, in the short term, have an improvement — or put another way, about 1 in 3, or put another way NNT = 3.

Part 3. Joe arrives

This is the most important part of the journal club—the practical application of what knowledge you have gained.

This is one way of doing it. Set out two chairs in consultation style.

Do not call for a volunteer—just nominate someone to be the clinician and you be Joe.

Make sure that the clinician feels they can have time to ask their [relieved for not being singled out] colleagues for help [remember—this has got to be a combination of practical and fun]. Back on page 2 there are suggestions for what Joe may ask—use them.

Well, Doc, what are my odds of getting better?

See if they can put across in a supportive way the best evidence as they understand it.

There is no perfect way to do this—but perhaps something like this: “The best evidence we have is from a Cochrane review - there is the impression that, for people not too dissimilar to you, about 1 in 3 people really show an improvement with Propantheline by only a few weeks.”

What do YOU mean by “improvement”? Would be a good next question.

Again there is no right answer but think about how to put into words what the research outcome really means.

Perhaps - “when compared with placebo, Propantheline is significantly more effective at reducing clozapine-induced hypersalivation. In practice, it means a reduction of the diameter of the wet patch on the pillow by over one third.”

As has been said—there is no right answer and all depends on personal style and situation. Your job is to encourage the best answer out of the clinician.

If it is going well there are other questions that you may ask—see side Box 1.

Limitations of using this means of calculating NNT is that is does not take into account the baseline risk of the control group and does not give confidence intervals.

In this case factoring in baseline risk of the control group does not make a difference.

NNT = 3, CI 2-5

http://www.nntonline.net/ebm/visualrx/what.asp

Box 1. Additional questions

What are my odds of getting better, Doc?

You could be numerical here—after all Joe is good with numbers—but do you understand them yourselves? Can you put Relative Risk into words?

How much of your salary would you put on me getting better in the next few weeks?

It may not be good practice to rise to this challenge literally—but it may be that some evidence-based deal could be arrived at with Joe and his parents. After all, data are only of 12 weeks duration. You could say that if he has not really noticed good effects by 12 weeks you would understand if he wanted to stop. To give it a consistent go up to 12 weeks does seem indicated.

What about the nasty side effects, Doc?

Well, there are some data (Gastric constipation). How do you use these limited data? Do you have to use other sources—after all small short trials are not great sources of rare important adverse effects. Remember Joe’s parents are there. What side effects will you give my son?

This can be part of a store of Critically Appraised Topics - see CATmaker online

End on a positive note. Feedback how in a matter of minutes they have got though the bare bones of a big review, appraised and applied it—and, you hope, enjoyed doing it.
Pharmacological intervention for clozapine-induced hypersalivation in schizophrenia
- HANDOUT FOR PARTICIPANTS

Produced by the Editorial base of the Cochrane Schizophrenia Group
http://szg.cochrane.org/en/index.html, email: jun.xia@nottingham.ac.uk

from

Service user will arrive soon
What do you think the service user may ask?
List:
1. 
2. 
3. 
4. 
5. 

What key points do you need to know to see if this review can help?*
1. 
2. 
3. 
4. 
5. 

*Service user arrives in 30 mins

Special points of interest:
- The idea of this is to lead you from the clinical situation, through the research and back to the real-world clinical situation again
- You may or may not have read the paper - but even if you have not that does not mean that you cannot get something out of this

- Make sure you participate, and speak up - you will have to in the real clinic
- There is no perfect way of doing this - each person has an individual way of interacting and conveying information

If you had not had this paper fall into your lap where might you have gone for reliable information?
After discussion do you want to change the key points you need to know to see if this review can help?*

1. 

2. 

3. 

*Service user arrives in 10 mins*

Can you extract numbers that will be useful to you and the service user? Clue: focus on what you think the service user may ask - main effects - graph 2.1.1 may be a good one to use

1. Can you put relative risk into words?

2. Can you work out the proportion of improvements attributable to use of Propantheline?

3. Can you work out the number needed to treat?

4. Can you put that into words?

Service user arrives
Is there a good use of words you would want to use?
Pharmacological intervention for clozapine-induced hypersalivation in schizophrenia - PARTICIPANTS’ CRIB SHEET

The three parts of appraising a review

1. Are the results valid?
   There is no point looking at the result if they are clearly not valid.
   a. Did the review address a clearly focused issue?
   Did the review describe the population studied, intervention given, outcomes considered?
   b. Did the authors select the right sort of studies for the review?
   The right studies would address the review’s question, have an adequate study design
   c. Do you think the important, relevant studies were included?
   Look for which bibliographic databases were used, personal contact with experts, search for unpublished as well as published studies, search for non-English language studies
   d. Did the review’s authors do enough to assess the quality of the included studies?
   Did they use description of randomization, a rating scale?

2. What are the results?
   a. Were the results similar from study to study?
   Are the results of all included studies clearly displayed?
   Are the results from different studies similar?
   If not, are the reasons for variations between studies discussed?
   b. What is the overall result of the review?
   Is there a clinical bottom line?
   What is it?
   What is the numerical result?
   c. How precise are the results?
   Is there a confidence interval?

3. Can I use the results to help the service user?
   a. Can I apply the results to the service user?
   Is the service user so different from those in the trial that the results don’t apply?
   b. Should I apply the results to the service user?
   How great would the benefit of therapy be for this particular person?
   Is the intervention consistent with the service user’s values and preferences?
   Were all the clinically important outcomes considered?
   Are the benefits worth the harms and costs?

A quick a dirty way to work out NNT (Graph 2.1.1)

26 people out of 47 given Propantheline were not clinically improved in the short term (55%) but 51 people out of 55 allocated to the placebo group did not improve in the short term (93%).

So, because a few people would have got better without Propantheline, the proportion attributable to taking Propantheline, according to these results, is the difference between the groups (or 93% minus 55% = 38%).

Just round up or down to make it easy. Let’s say, in this case, 40%.

So 40% of people in these trials, in the short term, have an improvement – or put another way, about 1 in 3, or put another way NNT = 3.
Pharmacological intervention for clozapine-induced hypersalivation in schizophrenia

- FEEDBACK

Date and place of journal club

1. How many attended?

   About

2. What was the background of the people attending? (please tick)

   Health care professionals

   Consumers

   Policymakers

   Undergraduate

   Postgraduate

   Others

3. Marks out of ten compared with usual journal club

   (10=much better, 5=same, 0 = much worse)

Free text feedback

Please return to:
Jun Xia
Cochrane Schizophrenia Group
Division of Psychiatry
University of Nottingham
The Sir Colin Campbell Building
Jubilee Campus
Innovation Park, Triumph Road
Nottingham
NG7 2RT
UK

E-mail:
jun.xia@nottingham.ac.uk
Tel: +44 (0)115 823 1287
Fax: +44 (0)115 823 1392

Thank you

This is one of 40 Cochrane Schizophrenia Group Guides for Journal Clubs

A full list is found on
http://szg.cochrane.org/journal-club